|Articles|February 1, 2013

Urology Times, Digital Edition, February 2013

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Jenny Guo, MD, discusses outcomes with hemi-HoLEP after pelvic radiation

ByJenny N. Guo, MD

June 16th 2026

Daniel Eun, MD, on telesurgery, AI, and the future of reconstructive urology

ByDaniel D. Eun, MD,Hannah Clarke

June 16th 2026

Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC

ByLouise Emmett, MD, PhD, MBChB, FRACP

June 16th 2026

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

ByToni K. Choueiri, MD

June 15th 2026

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer

ByHannah Clarke

June 15th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Urology Times, Digital Edition, February 2013

Related Content

Jenny Guo, MD, discusses outcomes with hemi-HoLEP after pelvic radiation

Daniel Eun, MD, on telesurgery, AI, and the future of reconstructive urology

Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Urology Times

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC